Assessment of the Therapeutic Potential of Enhancer of Zeste Homolog 2 Inhibition in a Murine Model of Bronchiolitis Obliterans Syndrome
Transplant International · 2024
DOI: 10.3389/ti.2024.13227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2024. Verfasst von Kyoto Matsudo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Bronchiolitis Obliterans, Enhancer of Zeste Homolog 2 Protein, Disease Models, Animal, Adenosine. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bronchiolitis obliterans syndrome (BOS) is a chronic complication following lung transplantation that limits the long-term survival. Although the enhancer of zeste homolog 2 (EZH2) is involved in post-transplantation rejection, its involvement in BOS pathogenesis remains unclear. We aimed to investigate the therapeutic potential of EZH2 inhibition in BOS. 3-deazaneplanocin A (DZNep) was administered intraperitoneally to heterotopic tracheal transplant recipient model mice. Tracheal allografts were obtained on days 7, 14, 21, and 28 after transplantation. The obstruction ratios of the DZNep and control groups on days 7, 14, 21, and 28 were 15.1% ± 0.8% vs. 20.4% ± 3.6% ( p = 0.996), 16.9% ± 2.1% vs. 67.7% ± 11.5% ( p < 0.001), 47.8% ± 7.8% vs. 92.2% ± 5.4% ( p < 0.001), and 60.0% ± 9.6% vs. 95.0% ± 2.3% ( p < 0.001), respectively. The levels of interleukin (IL)-6 and interferon-γ on day 7 and those of IL-2, tumor necrosis factor, and IL-17A on days 14, 21, and 28 were significantly reduced following DZNep treatment. DZNep significantly decreased the number of infiltrating T-cells on day 14. In conclusion, DZNep-mediated EZH2 inhibition suppressed the inflammatory reactions driven by pro-inflammatory cytokines and T cell infiltration, thereby alleviating BOS symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.
- Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
- Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
Zitieren
APA
Matsudo, K., Takamori, S., Takenaka, T., Shimokawa, M., Hashinokuchi, A., Nagano, T., Kinoshita, F., Akamine, T., Kohno, M., Toyokawa, G., & Yoshizumi, T. (2024). Assessment of the Therapeutic Potential of Enhancer of Zeste Homolog 2 Inhibition in a Murine Model of Bronchiolitis Obliterans Syndrome. Transplant International. https://doi.org/10.3389/ti.2024.13227
Vancouver
Matsudo K, Takamori S, Takenaka T, Shimokawa M, Hashinokuchi A, Nagano T, et al. Assessment of the Therapeutic Potential of Enhancer of Zeste Homolog 2 Inhibition in a Murine Model of Bronchiolitis Obliterans Syndrome. Transplant International. 2024. doi:10.3389/ti.2024.13227
BibTeX
@article{Matsudo2024,
author = {Matsudo, Kyoto and Takamori, Shinkichi and Takenaka, Tomoyoshi and Shimokawa, Mototsugu and Hashinokuchi, Asato and Nagano, Taichi and Kinoshita, Fumihiko and Akamine, Takaki and Kohno, Mikihiro and Toyokawa, Gouji and Yoshizumi, Tomoharu},
title = {Assessment of the Therapeutic Potential of Enhancer of Zeste Homolog 2 Inhibition in a Murine Model of Bronchiolitis Obliterans Syndrome},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.13227}
}
EUVIMED